Evaxion announces plan to implement ads ratio change

Copenhagen, denmark, jan. 08, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today announced that it plans to change the ratio of its american depositary shares (“adss”) to its ordinary shares, dkk 1 nominal value (the “ads ratio”), from the current one (1) ads representing one (1) ordinary share to a new ads ratio of one (1) ads representing ten (10) ordinary shares (the “ads ratio change”). the ads ratio change is expected to become effective on or about january 22, 2024, u.s. eastern time (the “effective date”).
EVAX Ratings Summary
EVAX Quant Ranking